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With the advent of DSM 5 criticism has generally centered on a lack of biological validity
of the diagnostic criteria. Part of the problem in describing a nosology of psychosis is the
tacit assumption of multiple genetic causes eachwith an incremental loading on the clinical
picture that fails to differentiate a clear underlying pathophysiology of high impact.The aim
of this paper is to consolidate a primary theory of deﬁcient muscarinic signaling underlying
key clinical features of schizophrenia and its regulation by several important genetic
associations including neuregulin, DISC and dysbindin. Secondary reductions in markers
for GABAergic function and changes in the levels of interneuron calcium binding proteins
parvalbumin and calbindin can be attributed to dysfunctional muscarinic transduction. A
parallel association exists for cytokine production. The convergent pathway hypothesis is
likewise used to model dopaminergic and glutamatergic theories of schizophrenia. The
negative symptom dimension is correlated with dysfunction of Akt and ERK transduction,
a major point of convergence. The present paradigm predicts the importance of a recent
ﬁnding of a deletion in a copy number variant of PLCB1 and its potential use if replicated,
as one of the ﬁrst testable biological markers differentiating schizophrenia from bipolar
disorder and further subtyping of schizophrenia into deﬁcit and non-deﬁcit. Potential
limitations of PLCB1 as a prospective marker are also discussed.
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INTRODUCTION
Acase for hypofunctioningmuscarinic transduction is gaining face
validity in schizophrenia research. Implicit memory dysfunction
and an imbalance of monoaminergic and in particular, dopamin-
ergic neurotransmission due to a primary muscarinic signaling
deﬁcit presents a novel paradigm for understanding schizophrenia
(Vakalopoulos, 2006). Explicit memory in schizophrenia as tested
on recall of paired associates can show performance comparable
to controls (Eyler et al., 2008). No unambiguous demonstration
of intact implicit memory has been demonstrated (Vakalopoulos,
2011). It is considered a core deﬁcit explained by the theory of
muscarinic receptor signaling deﬁcits.
A detailed account of how muscarinic dysfunction could
account for symptoms and endophenotypes of schizophrenia has
been proposed (Vakalopoulos, 2006). A previous paper showed
an imbalance between dopaminergic and cholinergic signaling
that could be corrected by neuroleptics (McGeer and McGeer,
1977). They revealed high ChAT (choline acetyltransferase) activ-
ities in a number of brain regions suggesting reduced muscarinic
receptor signaling. Glutamic acid decarboxylase (GAD) levels
were also noted to be low but in four patients they were ele-
vated in certain regions possibly suggesting secondary changes
in this enzyme rather than a primary etiology. A goal of this
paper is to show how many of the small effect sizes of genetic
variation and mutation impact on complex intracellular cascades
initiated by occupation of the muscarinic receptor. Mutations or
polymorphisms in DISC1, neuregulin and dysbindin can alter the
signaling capacity of the muscarinic receptor and thus, facilitate
hypersensitivity of dopaminergic transduction.
Innovative studies demonstrating the efﬁcacy of muscarinic
agonists in improving core schizophrenic both clinically and in
animal models provided a ﬁllip to further exploration of the role
of cholinergic neurotransmission beyond the nicotinic receptor
(Bymaster et al., 2002). Although M1–M5 subtypes are all impli-
cated in clinicopathological studies, most attention has focussed
on M1 and M4 receptors. Animal studies showed that in M4
knockoutmiceD1 dopamine receptor hyperresponsiveness occurs
in the striatum (Gomeza et al., 1999). Several of the authors
later propose an indirect mechanism for the pathophysiology of
psychosis involvingM4midbrain autoreceptors, a loss which para-
doxically increases cholinergic drive of dopaminergic nuclei and
neurotransmitter levels (Tzavara et al., 2004). A more direct effect
M4 deﬁcit on intracellular signaling and monoamine-muscarinic
imbalance was proposed as causal in declarative memory deﬁcits
associated with schizophrenia (Vakalopoulos, 2006, 2010).
M1 deﬁcit and monoamine imbalance is a parsimonious
explanation of broad domains of schizophrenic symptomatology,
including negative symptoms, memory deﬁcits, and psychosis.
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It is generally accepted that the main target of antipsychotics,
both typical and atypical, remains the D2 receptor. There is an
inverse modulation of signaling between M1 and D2 receptors
suggesting a dominant role for M1R dysfunction in schizophre-
nia. The relative lack of effectiveness of most agents in cognition
and motivation suggests a role for M1 not only as a potential
procognitive therapeutic target, but also implicates the path-
way in the causal nature of the disorder. Biochemical indices
commonly demonstrated in schizophrenia are altered by M1
and to a lesser extent M4 muscarinic receptor modulation.
Apart from GAD67 these include calcium binding proteins and
cytokines.
Finally, it will be argued that genetic variability and discovered
pathophysiological changes in schizophrenia support the ongoing
debate on distinct deﬁcit and non-deﬁcit subtypes (Strauss et al.,
2013; Kirkpatrick, 2014). The stated aim is to provide biological
underpinnings for these descriptors where relative muscarinic sig-
naling impairment and correspondingdeﬁcits in encoding implicit
emotional constructs are allied with avolition and apathy. These
are core negative features of the deﬁcit syndrome.
CONFLUENT PATHWAYS TO AFFECTIVE DYSREGULATION
A biological premise for implicit memory in affective disorders
(Vakalopoulos, 2007) was proposed to elucidate the signaling
pathways involved in the emotional dysregulation of psychotic
disorders (Vakalopoulos, 2010). Convergent signaling of N-
methyl-D-aspartate (NMDA), brain derived neurotrophic factor
(BDNF), dopamine D3R (Gi) and muscarinic M1R (Gq/11) is
involved in the learning and expression of emotional behav-
ior. BDNF and its tyrosine kinase receptor have a major
role in depression (Eisch et al., 2003). Key elements of the
intracellular pathways, ERK1/2 (extracellular signal-regulated
kinase) and PI3K/Akt (phosphatidylinositol 3-kinase and pro-
tein kinase B) cascades, are implicated in mood regulation
and addiction (Einat et al., 2003; Neasta et al., 2011). Con-
sistent with G-protein cross-activation, synergistic effects were
noted between Gi-Ras and Gq-PKC-dependent induction of
ERK (Blaukat et al., 2000) and is a model for D3-M1 inter-
active signaling effects. Although, these were independent of
tyrosine kinase and PI3K in this study, the muscarinic ago-
nist carbachol activates ERK1/2 via mitogen-activated protein
kinase (MAPK) that is protein kinase C (PKC) independent,
but Src (tyrosine kinase) and PI3K dependent (Rosenblum et al.,
2000). Dopamine D3 receptor (Gi), known to have a role in
addictive behavior, interacts with SH3 (Src homolog) domain
of growth factor receptor bound protein Grb2 and Src and
thus, is likely to signal ERK and Akt activation (Oldenhof et al.,
2001).
The phorbol ester PMA in a human breast cancer cell
line markedly activates the Raf-MEK (mitogen-activated protein
kinase kinase)-ERK but not PI3K-Akt pathway (Moelling et al.,
2002). Application of PMA mimics the activity of PKC kinases.
However, balanced activation is required for proliferation of cells.
Gi/o protein subunits Gβγ signals transactivation of tyrosine
kinases and PI3K-Akt pathway. This explains the importance of
conﬂuent signals that include not only D3R, but also colocaliza-
tion of M1/M4 receptors. It leads to the increased production
of necessary transcription factors involved in synaptogenesis and
the generation of neural networks that underlie memory traces
involved in emotional regulation.
The main effects of muscarinic M1 activation are mediated
on the one hand, by diacylglycerol (DAG) and inositol triphos-
phate (IP3), products of PLCβ1 (phospholipase C) activation
and on the other by PKC dependent and independent transac-
tivation of growth factor tyrosine kinases. The discovered PLCB1
haplo-insufﬁciency described below in psychosis would effectively
reduce the level of activated PKC isoenzymes and phosphorylated
ERK in some brain regions augmenting dopamine signal trans-
duction as in the basal ganglia. The relative integrity of the ERK
and Akt pathways could deﬁne affective symptom dimensions in
schizophrenia differentiating deﬁcit from non-deﬁcit subtypes.
Muscarinic sensitization of these pathways would underlie the
affective nature of psychosis in bipolar disorder and differentiat-
ing it from schizophrenia. The non-deﬁcit subgroup represents an
intermediate phenotype between bipolar and negative symptom
schizophrenia.
The forced swimming (FST) and tail suspension (TST) tests
are animal models of depression that use measures of immobil-
ity. This is associated with phosphorylation of ERK 1/2, JNK and
p38, members of the MAPK family. Blocking MEK, but also PKC
produced anti-depressant like behavior without affecting loco-
motor activity (Galeotti and Ghelardini, 2012). An increase in
platelet membrane-bound PKC activity was found in bipolar dis-
order patients in response to application of 5-HT (Friedman et al.,
1993;Wang et al., 1999). PKC response to acetylcholine (ACh) was
not tested. The latter measure would be expected to distinguish
bipolar disorder from schizophrenia.
A way of conceptualizing the affective dimension of psychosis
proposes a biochemical nomenclature: PLCβ1−/−, PLCβ1−/+
and PLCβ1+/+, where + and – represent normal and deﬁcient
allelic or pathway expression to a balanced ERK andAkt activation.
Abnormal sensitization of PLCβ1+ (affective dimension) where
the integrity of the pathway is preserved would involve conﬂuent
and dysregulated mechanisms upon the M1 signal. Some support
for this thesis comes froma study stimulatingmuscarinic receptors
in humanneuroblastoma cells (Grimes and Jope,1999). Carbachol
resulted in a potent increase of neural growth factor (NGF1-A/Egr-
1) protein levels andDNAbinding activity. This effect was reduced
by down regulation of PKC (85%), lower calcium levels (25–35%)
and tyrosine kinase inhibitor (35%). Inhibition of MEK1/2 and
the mood stabilizer valproate, but not lithium nor carbamazepine,
reduce activation by 60%.
NMDA AND M1 RECEPTOR RESPONSES
Di Chiara et al. (1994) claim that medium spiny striatal neurons
are only indirectly affected by non-competitive NMDA antago-
nists. A primary action on large aspiny cholinergic neurons is
proposed (Di Chiara et al., 1994; Vakalopoulos, 2006). The lat-
ter are tonically active. Blockade of NMDA receptors on D1 and
D2 mediated responses in an experimental model of dopamine
deﬁciency resembles that of scopolamine a muscarinic recep-
tor antagonist (Damsma et al., 1991). Dizocilpine (MK-801), a
commonly used non-competitive NMDA antagonist, not only
reduces D1-dependent ACh release, but also basal ACh levels.
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ACh itself enhances striatal NMDA responses via the muscarinic
M1 receptor (Calabresi et al., 1998) showing convergence of path-
ways. It also suggests that the psychosis-inducing effects of NMDA
antagonists aremediated throughmuscarinic inhibitionboth indi-
rectly, via reduction of the tonic ﬁring of cholinergic striatal
neurons and directly, through its effects on muscarinic receptor
transduction.
Positive allosteric modulation of M4R reverses MK-801-
induced hyperlocomotion and mice model of cognitive deﬁcits
(Bubser et al., 2014). NMDA is the excitatory neurotransmit-
ter for large aspiny cholinergic striatal neurons (Vakalopoulos,
2006). Thus, the effects of MK-801 are to a large extent indirectly
mediated through striatal cholinergic neurons acting on separate
populations that express either M1 or M4 receptors.
Physiological levels of NMDA have been shown to increase
both pAkt and pERK (active forms) in an inverted U-type func-
tion independent of PKC (Sutton and Chandler, 2002). It involves
Gβγ subunit of heterotrimeric Gi/o-protein, PI3K, and calcium.
The neuroprotective effects of NMDA require BDNF secretion
(Marini et al., 1998). TheNMDAantagonist phencyclidine reduces
the number of synaptic sites and expression of synaptic proteins
by downregulating Trk and these changes are rescued by applica-
tion of BDNF (Adachi et al., 2013). BDNF also activates pAkt, but
is independent of extracellular calcium (Perkinton et al., 2002).
Optimally effective memory formation and associated synap-
tic consolidation probably requires signal convergence of several
distinct ligand-receptor couplings.
PROLIFERATIVE PATHWAYS IN SCHIZOPHRENIA
Excessive or unbalanced functional signaling of Raf-MEK-ERK
and PI3K-Akt-mTOR has been strongly implicated in cancer
formation (Steelman et al., 2011). mTOR (mammalian or mecha-
nistic target of rapamycin) is a major focal point of convergence of
many signaling pathways that lead to protein and lipid synthesis
and metabolic regulation (Laplante and Sabatini, 2009). Rates of
cancer incidence are signiﬁcantly reduced in relatives and patients
especially prior to ﬁrst diagnosis of schizophrenia (Ji et al., 2013).
This ﬁnding ismaintained only inmales after diagnosis, but overall
supports the putative deﬁcient pathway in schizophrenia. In fact,
both M1-like and M2-like signaling can phosphorylate Akt and
ERK messengers (Kajiya et al., 2012; Wu and Wong, 2006) and is
abrogated by regulators of G-protein signaling (RGS; Anger et al.,
2007).
A cholinergic autocrine loop for many cancers has been
established with muscarinic (M3) agonists increasing and antag-
onists decreasing tumor growth (Spindel, 2012). However, as
in schizophrenic therapeutics muscarinic modulation in cancer
remains theoretical and experimental.
Wnt AND β-CATENIN PATHWAYS
The transcription of the mouse proto-oncogene Wnt (wingless/
integration) is secreted as a glycoprotein and interacts with
its receptor Frizzled and a coreceptor low density lipoprotein
receptor-related protein (LRP5/6). Transcription via the cyto-
plasmic scaffold protein Disheveled (Dvl) prevents sequestration
and thus, degradation of β-catenin by a complex that critically
includes glycogen synthase kinase (GSK3; Clevers and Nusse,
2012). The canonical β-catenin and Wnt induction of mTOR
regulates stem cell fate (Iglesias-Bartolome and Gutkind, 2011).
There are also non-canonical Wnt pathways activating the kinase
JNK and calcium signaling and that share a role in neurodevel-
opment and mature synaptic remodeling (van Amerongen and
Nusse, 2009).
The non-canonical pathway upregulates synaptic NMDA
receptor currents (Cerpa et al., 2011). Wnt-2 mediated activity-
dependent dendritic arborization conversely, depends on NMDA
calcium currents, calmodulin-dependent protein kinase acti-
vated Ras/MEK/ERK and CREB-dependent transcrption of Wnt
2 (Wayman et al., 2006). Synaptogenesis associated increases in
dendritic spine density is also stimulated by BDNF induction of
CREB transcrition (Lesiak et al., 2013). Tyrosine receptor kinases
facilitate activation of the canonical Wnt/β-catenin pathway via
ERK/LRP6 (Krejci et al., 2012). Another studyusing rat hippocam-
pal slices showed that late phase long-term potentiation (LTP)
under weak synaptic stimulation can be achieved only in the
presence of the β-agonist isoproterenol (Ma et al., 2011). Akt inac-
tivates GSK3 by phosphorylation, in turn activating mTOR,which
also requires Wnt signaling. NMDA antagonist APV-5 blocks LTP
and abolishes Wnt3a-mediated nuclear localization of β-catenin
(Chen et al., 2006).
M1 muscarinic agonists likely enhance Wnt pathways by at
least, a PKC mediated inactivation of GSK3 (Inestrosa and Toledo,
2008). It has in fact been shown that M1 muscarinic receptor and
the growth factor receptor (EGFR) mediate proliferation of pro-
genitor cells in salivary gland (Knox et al., 2010). GαqmediatesM3
muscarinic reduction in GSKβ activity and increase in β-catenin
accumulation (Salmanian et al., 2010).
In mouse models of learning Wnt signaling in the amygdala is
necessary for late consolidation of a fear-conditioning task where
initial acquisition is unimpaired by local application of Wnt1 or
its inhibitor Dickkopf-1 (Dkk-1; Maguschak and Ressler, 2011).
Initial decrease in β-catenin destabilizes synapses allowing modi-
ﬁcation by reduced binding to the cell adhesion molecule cadherin
with a subsequent restoration of the complex for consolidation.
BDNF increases synaptogenesis by also disrupting these complexes
presynaptically (Bamji et al., 2006). Mice with Dkk-1 infused into
the dorsal hippocampus showed no distinction in exploring a
novel object from a familiar one introduced 24 h earlier suggesting
loss in object recognition (Fortress et al., 2013). This was asso-
ciated with a signiﬁcant decrease in phospo-GSK3β, its inactive
form.
There is thus, a complex interplay between various recep-
tors and their signaling cascades and subtle differences in
transduction that might result from a dynamic balance of
monoamine-muscarinic cholinergic coactivation of neuronal
synapses could signal a modiﬁed course of Hebbian plasticity.
This means that varying the monoamine-muscarinic signal is
categorical for cognition and ﬂexible behavior. Thus, a puta-
tive dual model of hierarchical control of signal transduction
is represented at a molecular level by enhancement of single
synaptic events or dendritic formation associated with rein-
forcement to remolding of networks and attrition of synapses
in the context of new contingencies that require adaptive
change.
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Wnt AND SCHIZOPHRENIA
Schizophrenia is regarded as a neurodevelopmental disorder,
however, it is unclear whether the Wnt signaling cascade itself
directly contributes to risk (Panaccione et al., 2013). A study
that looked at peripheral blood Wnt biomarkers of 19 patients
with a DSM-IV diagnosis of psychosis and using the scales for
the assessment of positive (SAPS) and negative (SANS) symp-
toms found that SANS, but not SAPS was correlated with several
factors (Bousman et al., 2013). A negative correlation was signif-
icant for Dvl, trending for a transcription factor in the canonical
pathway (TCF4) and a positive correlation approaching signif-
icance for GSK3. Dvl1 knockout mice exhibit reduced social
behaviors and sensorimotor gating as measured by prepulse
inhibition of acoustic and tactile startle responses (Lijam et al.,
1997).
Pathognomonic learning impairments have been proposed
for schizophrenia and these should reﬂect signaling changes. It
remains important to describe these correlations in higher-level
psychological terms (Vakalopoulos, 2010). An elegant study in a
group of 15 patients with a DSM IV diagnosis of schizophrenia
or schizoaffective disorder showed a profound deﬁcit in LTP-like
enhancement of motor evoked potential (MEP) amplitude during
a paired associative stimulation paradigm (Figure 1). The exper-
iment involved pairing of median nerve electrical stimulation
with transcranial electrical stimulation TMS of the correspond-
ing contralateral motor area (Frantseva et al., 2008). The same
patients demonstrated no learning on a rotary pursuit task, a mea-
sure of skill learning (Figure 2). Patients failed to improve their
ability to stay on target for longer periods of time compared to
controls.
The graphs suggest a speciﬁc and fundamental principle of cog-
nitive impairment in schizophrenia that has not been sufﬁciently
appreciated. Most reaction time experiments in this group show
improvement in spite of overall and maintained marked slowing
in performance compared to normal subjects. This is taken, unrea-
sonably, to show skill learning, i.e., in the non-declarative sense.
However, the current results clearly demonstrate a core deﬁcit
FIGURE 1 | Effect of PAS on MEP amplitude. Values represent a ratio of
post-/pre-MEP amplitude. Values greater than 1 (dashed line) represent a
PAS-induced MEP facilitation. Results demonstrate that patients with SCZ
demonstrated no MEP facilitation (Frantseva et al., 2008).
FIGURE 2 | Impaired motor skill learning in SCZ. Data represent mean ±
standard deviation acquired for each of the three blocks of data acquired.
Motor skill learning was derived through the rotary pursuit task. In this
task, participants are required to hold a stylus upon a ﬂat surface under
which the target rotated and follow the target as it moved about its path. A
photoelectric device measured the time (in seconds) that the stylus was
held correctly over the target for each trial. Each block of skill learning
consisted of eight 20-s trials with a 20-s intertrial interval. These data
suggests that unlike healthy subjects, patients with SCZ failed to
demonstrate signiﬁcant motor learning (Frantseva et al., 2008).
in this type of learning. Rotary pursuit, as tested in this study,
can be taken as a relatively pure measure of procedural learning
where overt strategy contributes little to improved time on target,
whereas improvement in conscious control can index slow RT
improvements in other tasks.
Further, a special relationship is suggested between speciﬁc
aberrations in intracellular signaling and the negative symptom
dimension in schizophrenia, which is manifested as synonymous
impairments in procedural or skilled acquisition or more broadly,
implicit memory.
GENE DELETIONS AFFECT MUSCARINIC SIGNALING IN
PSYCHOSIS
A study identiﬁed a deletion of the PLCB1 gene (Figure 3) in
the orbito-frontal cortex for 4 of 15 post-mortem schizophrenic
patients (Lo Vasco et al., 2012). The PLCβ signaling pathway
transduces Gq/11. In a mouse model of PLCβ1 deletion selec-
tive attenuation of muscarinic M1 and not serotonin-induced
5-HT 2A/2C phosphoinositide hydrolysis was demonstrated (Kim
et al., 2007), suggesting speciﬁcity to this signaling pathway.
Microarray studies have shown reduced mRNA for PLCβ1 in the
dorsolateral prefrontal cortex (DLPFC) of schizophrenic patients.
Widespread cortical muscarinic receptor decreases in a subset
of probands has already established a precedent for an index of
dysfunction along this pathway (Gibbons et al., 2013). The sig-
niﬁcance of muscarinic receptor deﬁcits now appears clearer as
a secondary change to genetic events like PLCB1 microdeletions.
PLCB1 KO mice display typical endophenotypes for schizophre-
nia and reduced levels of M1 receptor binding (McOmish et al.,
2008).
In three of the four positive cases reported by Lo Vasco
et al. (2012) a single allele deletion was present in practically
all nuclei analyzed. In two of these the mode of death was
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FIGURE 3 | Molecular cytogenetic analyses of normal control and schizophrenia affected patients. (i) Normal control, (ii) mono-allelic deletion, and (iii)
bi-allelic deletion (Lo Vasco et al., 2012).
suicide. In the other patient both alleles were deleted in 76%
of nuclei and a single allele in the remaining 24%. This patient
did not commit suicide. The low numbers and lack of clini-
cal descriptors make it difﬁcult to draw any ﬁrm conclusions,
but monoallelic versus deletion of both alleles are a potential
concomitant of a non-deﬁcit/deﬁcit dichotomy, respectively. In
another study on patients with major depressive disorder no
such deletions of the PLCB1 gene were discovered (Lo Vasco
et al., 2012) highlighting the distinction in nosology between
affective and psychotic illness. 26% of the schizophrenic sam-
ple demonstrated deletions of the PLCB1 allele, but none of the
normal controls and this ﬁgure may prove to be higher with
the use of smaller probes. A study of high-density Irish fami-
lies for psychotic illness demonstrated a linkage to chromosome
20p close to the locus for PLCB1 (Fanous et al., 2008). Deﬁcit
syndrome had the highest LOD score of any latent class for the
genome.
In a post-mortem brain study of 15 bipolar subjects bipolar
disorder (BPD) a single deletion of PLCB1 was discovered in only
one sample (LoVasco et al., 2013). The association of PLCB1 dele-
tion and bipolar disorder appears much weaker assuming a valid
initial diagnosis of BPD. Alternatively, based on the predictive
strength of the theory of a muscarinic transduction deﬁcit, a bio-
logical marker could determine unambiguously the nosological
category of a case of psychosis and the positive bipolar post-
mortem case in this instance would be conﬁdently reclassiﬁed
as schizophrenic. A distinction was made in subgroups of psy-
chotic disorder when ascertaining phosphorylation of Akt (pAkt)
by neuregulin-1 (NRG-1) stimulation of ErbB receptor in B lym-
phoblasts (Kéri et al., 2009). The ratio pAkt/Akt was signiﬁcantly
reduced in schizophrenia, but those with bipolar or major depres-
sive psychosis did not differ fromcontrols. All psychotic subgroups
were similarly impaired, highlighting the nosological speciﬁcity of
the signaling pathway.
A further analysis of the categorical signiﬁcance of single
versus double deletions of PLCB1 alleles is warranted. A par-
tial dysfunction of the M1 signal augments catecholaminergic
transduction. None the less, there is some conservation of
the convergent M1-NMDA signal on Ras-ERK and PI3K-
Akt intracellular pathways involved in affective dysregulation.
Thus, the high suicide rate in single allele deletion. No
such behavioral association would be expected with dou-
ble allelic deletions, i.e., a more profound disruption of
Akt and ERK pathways and a putative predictor of deﬁcit
syndrome.
THE PARADOX OF RELATIVE VERSUS ABSOLUTE DEFICITS
The concept of convergent signaling states that the primary deﬁcit
in the muscarinic receptor and its transduction products creates
a relative imbalance of monoaminergic cholinergic internal states
of a neuron. In attention deﬁcit hyperactivity disorder ADHD
recent studies demonstrated a 50% reduction in muscarinic
receptor binding (Coccini et al., 2009; Johansson et al., 2013).
However, it has been proposed that a defective catecholaminer-
gic response unmasks cholinergic muscarinic mediated prepotent
behaviors (Vakalopoulos, 2007). This suggests the muscarinic
ﬁndings are secondary. An explanatory model comes from an
altogether different body system, the pulmonary airways. Respec-
tively β2-adrenergic (β2AR) and muscarinic M3 agonism produce
bronchodilation and bronchoconstriction and this classic under-
standing of antagonist effects is the basis of asthma therapeutics.
In contrast to its bronchodilator effect chronic use of β-agonists
leads to a sensitized mechanism of brochoconstriction. Transgenic
mice either lacking β1 and β2 receptors (βAR−/−) or overex-
pressing βARs in airway smooth muscle caused a reduction of or
enhancedbronchoconstriction, respectively (McGraw et al., 2003).
Notably, PLCβ1 protein level is reduced by 60% in βAR−/− mice,
but is at twice the basal level in mice overexpressing the recep-
tors. Thus, adrenergic stimulation modulates protein expression
of a key muscarinic signaling pathway. Deletion of the PLCB
gene was previously described to be associated with muscarinic
receptor reduction and may explain the ADHD ﬁndings of abso-
lute reduction but putative relative increase in the muscarinic
signal.
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GENE MARKERS OF RISK PATHWAYS IN SCHIZOPHRENIA
A model of hypomuscarinic transduction offers a heuristic
approach to multifactorial genetic associations that converge on
this pathway. A good example of this is the candidate gene for
schizophrenia RGS4 (regulator of G-protein signaling). RGS4
directly modulates Gq/11 and Gi subclasses of Gα subunits, but
not Gs (Druey et al., 1998). Further, this negative regulator of
G-protein signaling directly interacts with PLCβ1 (Dowal et al.,
2001).
DISC1, neuregulin-1 (NRG-1) and dysbindin are commonly
implicated genetic risk loci of the disease. These gene transcripts
have complex effects in neurodevelopment and adult synaptic
plasticity, and are directly involved in signaling cascades impli-
cated in disease generation. DISC1 and neuregulin 1 transcend
the traditional dichotomy in psychiatric diagnosis, demonstrat-
ing susceptibility for an affective spectrum of psychosis from
schizophrenia to bipolar disorder and even major depression (St.
Clair et al., 1990; Green et al., 2005; Balu and Coyle, 2011). NRG-1
is also associated with a non-deﬁcit subtype of schizophrenia.
A knockdown of DISC1 in newborn neurons of the adult brain
does increase Akt activity (Kim et al., 2009). NRG-1 activates
MAPK (ERK) and PI3K via ErbB4 tyrosine kinase receptor and
both NRG-1 and ErbB4 are elevated in the prefrontal cortex of
schizophrenic patients (Chong et al., 2008) or at least enhanced
transduction is noted in post-mortem brains (Hahn et al., 2006).
The ErbB4 risk haplotype for schizophrenia is associated with
increased levels of transcript for the catalytic subunit of PI3K,
p110δ (Law et al., 2012). This in fact, reduces levels of PI(3,4,5)P3
and presumably phosphorylatedAkt. The effects are speciﬁc to the
PI3K pathway because no genetic effects of the ErbB4 risk haplo-
type were found on ERK-MAPK signaling. This and the fact that
PKC only weakly activates PI3K-Akt and high Akt activity sup-
presses ERK (Moelling et al., 2002) suggests selective dysfunction
of closely related pathways and is of putative relevance to dissocia-
tion of the negative symptom dimension in psychosis. The effects
of DISC1 and neuregulin 1 on ERK and Akt pathways explain,
at least partly, the prominence of associated mood disorders. In
other words, the manifestation of mood symptoms depends on
the relative preservation of signal transduction involving Akt and
or ERK.
Dysbindin is reduced in the prefrontal cortex of patients
(Weickert et al., 2004). Downregulation of dysbindin expres-
sion suppresses PI3K pathway and Akt phosphorylation levels
(Numakawa et al., 2004). Several studies have demonstrated that
psychotic individuals with a high-risk haplotype of dysbindin may
be associated with more pronounced negative symptoms (Fanous
et al., 2005; DeRosse et al., 2006; Corvin et al., 2008).
These same geneticmarkers also have effects on neurotransmit-
ter imbalance potentiating monoaminergic transduction. DISC1
is associated with reduced cytosolic PDE4 impairing breakdown
of cAMP and raisedNRG-1 reducesNMDA efﬁciency (Hahn et al.,
2006). Mutant astrocyte DISC1 in mouse models reduces NMDA
transmission by decreasing D-serine levels (Ma et al., 2013)
NEUREGULIN-1: A MODEL CONVERGENCE OF GENETIC RISK
Phenotypic expression of NRG-1 mutations in animal mod-
els implicate dysregulation of the muscarinic receptor and an
imbalance of catecholaminergic effector response. Dilated pupils
in a NRG-1 mouse mutant did not respond to the non-speciﬁc
muscarinic agonist pilocarpine and showed a concomitant reduc-
tion of the muscarinic M3 receptor in the sphincter pupillae
(Chen et al., 2011). This partial loss of function mutant induced a
decrease in EGF-type neuregulin isoforms. Treatment of isolated
chick atrialmyocytes withNRG-1 (EGF-like domain) also induced
a decrease in muscarinic M4 receptor mRNA and carabachol
(cholinergic agonist)-evoked outward rectifying currents (Ford
et al., 2003). Cardiomyocytes were treated with the β-adrenergic
agonist isoproterenol and the antagonizing response to carbachol
was tested in wild-type and mice heterozygous for NRG-1 dele-
tion (Okoshi et al., 2004). Although M2R and Gi/o protein levels
were normal in heterozygous mice, carbachol failed to attenuate
raised intracellular calcium and contractile responses. The anti-
adrenergic effects of NRG-1 itself are blocked by the muscarinic
receptor antagonist atropine (Lemmens et al., 2005).
DISC1 AND VENs
von Economo neurons (VENs) are large spindle-shaped neu-
rons in layer V of predominantly the frontoinsular (FI) cor-
tex and more irregularly in the anterior cingulate cortex
(Figure 4). They possess single basal and apical dendrites
with restricted branching that span most layers (Watson et al.,
2006). The locations of VENs overlap with neurons that project
to the nucleus Basalis of Meynert from the anterior granu-
lar insula (Figure 5). They could speciﬁcally serve cholinergic
corticopetal activation, a function proposed for the agranu-
lar insula in implicit memory encoding (Vakalopoulos, 2010,
2013).
Ninety percentage of VENs are DISC1 positive, while only 37%
of other layer V neurons are likewise positive (Allman et al., 2010).
That they are potentially important in neuropsychiatric disease is
suggested by the ﬁnding of a signiﬁcant reduction in density of
VENs in the anterior cingulate cortex inversely related to duration
of illness in schizophrenia, but not bipolar subjects (Brüne et al.,
2010). Mutations of DISC1 gene would be expected to alter the
output of VENs and inducing a relative hypocholinergic state.
bvFTD
The behavioral variant of frontotemporal dementia (bvFTD) is
characterized by insidious changes in personality including social
withdrawal, apathy and emotional blunting, but also marked
stereotypies (Harciarek et al., 2013; Pose et al., 2013). The clin-
ical proﬁle overlaps most notably with negative symptoms of
schizophrenia and is consistent with deﬁcient cortical choliner-
gic input to cortex. This is presumably mediated through cortical
M1R. Although, the positive symptoms of psychosis are relatively
low in FTD (up to 13.3%), those patients with speciﬁc genetic
mutations can have much higher rates (up to 40%; Piguet and
Hodges, 2013). One of the most characteristic post-mortem ﬁnd-
ings in bvFTD is frontoinsular degeneration with loss of over 50%
of VENs and fork cells (Kim et al., 2012).
Diagnoses of schizophrenia, schizoaffective, and bipolar dis-
orders can be made early in the course of bvFTD (Velakoulis
et al., 2009). Also schizophrenia-related psychosis is observed sig-
niﬁcantly more frequently in family members of FTD probands
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FIGURE 4 | von Economo neurons are present in LayerV of primate insula cortex (Allman et al., 2010).
FIGURE 5 | Projection neurons from the insula deep layers to the
cholinergic basal forebrain (Russchen et al., 1985).
than those with Alzheimer’s disease (Schoder et al., 2010). The
acetylcholinesterase inhibitor rivastigmine mitigated behavioral
changes as measured by the Neuropsychiatric Inventory including
psychotic symptoms in an open label study of FTD (Moretti
et al., 2004). Treatment of FTD with antipsychotics is generally
regarded as ineffective. However, in another study donepezil
did worsen clinical state (Mendez et al., 2007). The con-
tradiction may be explained by the ﬁnding that donepezil
has antagonistic properties at muscarinic receptors (Ago et al.,
2011).
GAD67, INTERNEURON MARKERS AND THE M1 RECEPTOR
The 67 kDa isoform of the glutamate decarboxylate mRNA, a
GABA synthesizer, is reduced in the DLPFC of schizophrenic
subjects in the absence of obvious cell loss. The study included
non-medicated patients (Akbarian et al., 1995). 50% of DLPFC
parvalbumin (PV) mRNA+ neurons in this group lack detectable
levels of GAD67 mRNA compared to only 10% in normal
controls (Hashimoto et al., 2003). Levels of PV, a calcium-
binding protein are also reduced, although PV-expressing cells
may be normal in number (Lewis et al., 2008). Overall, 25–
35% of GABA neurons lack the transcript for GAD67 mRNA
in schizophrenic cohorts. Reductions are not speciﬁc to PV
neurons, but also involve mRNA for interneurons expressing
somatostatin (SST)/neuropeptide Y (NPY) and for the GABA
membrane transporter, GAT-1. These changes in schizophre-
nia extend to other cortical areas including anterior cingu-
late, primary motor and primary visual regions (Hashimoto
et al., 2008). GAT-1 regulates reuptake of synaptically released
GABA. Using magnetic resonance spectroscopy (MRS) centered
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on bilateral calcarine sulci, a study found a signiﬁcant 10%
decrease in GABA levels in schizophrenic subjects (Yoon et al.,
2010).
Up to half of SST+ and 80% of PV+ interneurons express
tropomyosin-related kinase (TrkB; Gorba and Wahle, 1999), a
tyrosine kinase receptor for BDNF. TrkB and BDNF mRNA
transcripts are reduced in DLPFC schizophrenic patients and a
signiﬁcant correlation exists between TrkB, but not BDNF and
GAD67 (Hashimoto et al., 2005; Weickert et al., 2005). Calretinin
immunopositive neurons appear not to be affected and do not
express TrkB.
It was suggested that deﬁcient neurotrophin signaling is an
upstream causal event in decreased expression of GABA mark-
ers (Lewis et al., 2005). ErbB4, the tyrosine kinase receptor for
neuregulin-1, is expressed exclusively on GABAergic interneurons
and 50% of these are PV-IR (immunoreactive; Fisahn et al., 2009;
Buonanno, 2010). The cytoplasmic tails of ErbB4 receptor and
NMDA N2A and N2B subunits interact through the post-synaptic
density protein (PSD-95; Garcia et al., 2000). PSD-95 is a mem-
ber of the membrane-associated guanylate cyclases (MAGUKs)
involved in signal transduction. The non-speciﬁc muscarinic
antagonist scopolamine reduces the expression of BDNF, but
also neuronal cell markers including PSD-95 (Konar et al., 2011).
Repetitive animal exposure to the NMDA antagonist ketamine
causes a reduction in the expression of GAD67 and PV (Behrens
et al., 2007).
In striate visual cortex (V1) of the macaque monkey PV-IR
neurons constitute∼75%of inhibitory neurons (Disney andAoki,
2008). 87% of these express M1 muscarinic receptor, compared
with only 40% of CR cells. M2 muscarinic receptors are expressed
in 32% of PV+ cells suggesting substantial but limited overlap
in M1 and M2-expressing cells. Vakalopoulos (2006) considers
colocalization to be governed by a dominant subtype, M1- or M2-
type for any particular group of neurons. Parallel to PV ﬁndings
in macaque V1, 93% of rat striatal neurons expressing SST were
labeled by a probe for M1R, but only 15% by M4 probe (Bernard
et al., 1992). Thus, M1R deﬁcient signaling in schizophrenia can
explain reductions in BDNF, GAD and calcium binding protein
markers.
Interleukin-4 (IL-4) applied to retinal rat cell cultures increased
uptake of [3H]-GABA in a dose-dependent manner and was
blocked by an inhibitor of the GAT-1 transporter (Sholl-Franco
et al., 2002). This effect was dependent on M1R, protein kinase
C (PKC), intracellular calcium levels and a tyrosine kinase recep-
tor. A 90% increase in GAD67 expression was also induced by
IL-4. The klotho mutant strain of mice demonstrate reduced
phosphorylation of hippocampal janus kinase 2 (JAK2) and sig-
nal transducer and activator of transcription (STAT3; Park et al.,
2013). This induces a reduction in several cholinergic parameters
and a selective loss in protein expression and binding den-
sity of M1 muscarinic receptor and a concomitant decrease in
PKCBII, p-ERK, p-CREB, and BDNF. NMDA-dependent LTP is
also impaired. All transcript reductions and LTP are reversed by
the purported M1R agonist, McN-A-343. The normalizing effects
of McN-A-343 are in turn reversed by a BDNF receptor tyrosine
kinase inhibitor suggesting mediation of the muscarinic agonist
effects. However, non-selectivity and complex effects have been
reported forMcN-A-343 includingM4Ragonismand serotonergic
effects.
Although, GABA related interneuron ﬁndings are amongst the
most robust in post-mortem schizophrenic samples they are also
present to a variable degree in mood disorders. PV is reduced in
Brodmann area 9 of DLPFC of BPD and SST in major depressive
disorder (MDD), but not GAD67 (Sibille et al., 2011). However,
GAD67 is reduced in the orbitofrontal cortex (OFC) and CA4
region of the hippocampus in non-psychotic MDD and TrkB in
CA4 region of BPD (Thompson et al., 2009, 2011). GAD67 is also
down in the OFC of BPD. This suggests that GAD67 does not
directly contribute to the psychotic phenotype. The overlap of
deﬁcient GABA markers may result from a common reduction in
neurotrophic BDNF protein density (Dunham et al., 2009).
THE SPECIAL CASE OF CALBINDIN
The density of calbindin immunoreactive neurons CB-IR in
the prefrontal cortex, areas 9 and 46, of a small number of
schizophrenics was 50–70%greater thanmatched controls (Daviss
and Lewis, 1995). The reactivity was largely from interneurons of
the superﬁcial layers and the magnitude of the increase would
suggest change in neuronal number. A non-signiﬁcant increase
in calretenin-IR was also found. This was an immunohisto-
chemical study and other similar studies showed no (Tooney
and Chahl, 2004) or even decreased CB-IR (Beasley et al., 2002).
However, a study looking at mRNA transcripts of calcium bind-
ing proteins CBP showed a 14.9% rise in CB, while most other
interneuron markers were reduced including PV, somatostatin,
cholecystokinin, vasoactive intestinal protein VIP and neuropep-
tide Y (Fung et al., 2010). The same research group replicated
an increase of 22.7% in CB of a separate cohort (Fung et al.,
2014). Although they reported decreases in somatostatin and
VIP mRNA in the prefrontal cortices of both schizophrenic and
bipolar disorder subjects, only CB discriminated between them.
There was a relative increase of 22.5% in CB in schizophrenics
and the level in bipolar disorder did not differ from controls
(Figure 6). The reason for the discrepancies between some
of the studies is not entirely clear, but methodology or sub-
group selection can have profound effects on results. Further,
phenotypic expression does not always match changes in gene
transcription.
Raised calbindin IR and mRNA are a signiﬁcant deviation from
more general reductions in interneuronmarkers. This suggests dif-
ferences in neuromodulatory effects. 60% of CB-IR neurons (12%
of the GABAergic population) express M1 muscarinic receptors
(Disney and Aoki, 2008). In an animal model of PLCB1 deﬁciency
homozygous PLCB1 knockout mice showed a 3-fold increase in
the number and density of hippocampal granule cells compared to
wild-type litter-mates (Manning et al., 2012). Phenotypic analysis
with confocal microscopy showed these to be mature cells express-
ing CB. No other relevant markers were assessed, but the data are
consistent with the selective increase in CB being related to M1R
transduction deﬁcits.
Schizophrenia butnot bipolar nor controls showedan increased
expression of NR2A mRNA by calbindin-containing interneu-
rons of the anterior cingulate cortex (Woo et al., 2008). The
same group demonstrated undetectable levels of NR2A mRNA
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FIGURE 6 |The interneuron protein marker calbindin is elevated in
schizophrenia, but bipolar subjects do not differ from controls (Fung
et al., 2014).
co-expressed in up to 73% of GABAergic interneurons of both
schizophrenia and bipolar subjects (Woo et al., 2004). Although
the former study did not reveal overall changes in calbindin
mRNA, it does suggest a selective proliferative capacity of CB-
IR neurons in schizophrenia. Long-term scopolamine use in rats
reduces the NMDA subunit NR2A protein levels in the anterior
cingulate cortex conﬁrming amuscarinic interaction (Doguc et al.,
2012). The NMDA antagonist MK-801 in perinatal mice caused
an increase in CB and reduction in calretinin mRNA as well as
reduced PV immunoreactivity in the medial prefrontal cortex
mPFC (Gilabert-Juan et al., 2013). A point mutation of the DISC1
gene in mice also resulted in reduced PV-IR neurons of the mPFC
and increased CB-IR in the DLPFC compared to wild-type (Lee
et al., 2013).
CYTOKINES
Abnormal regulation of inﬂammatory markers in schizophre-
nia is considered by some investigators as pointing to a possible
causal etiology. Alternatively, putative transduction deﬁcits by
neuromodulators of peripheral blood mononuclear cells could
be an incidental window into core disturbances within the central
nervous system.
In vitro stimulation of interleukin-2 (IL-2) production by
T lymphocytes is clearly deﬁcient in a subset of schizophrenic
patients (Villemain et al., 1989). More than half of the patients in
this study did not show reactivity above baseline including all three
patients with undifferentiated subtype. This has been replicated in
both treated and untreated patients and in further in vitro and
in vivo studies consistent with the status of a trait marker (Bessler
et al., 1995; Arolt et al., 2000; Asevedo et al., 2014). A meta-analysis
of cytokines in schizophrenia also found a consistent elevation of
interleukin-6 (IL-6; Potvin et al., 2008).
Positive and depressive symptoms were unrelated to IL-2 lev-
els, but a negative correlation was described between IL-2 and
negative symptoms and positive correlation with age of onset
(Ganguli et al., 1995; Asevedo et al., 2014). Further, IL-6 levels
were signiﬁcantly higher in deﬁcit versus non-deﬁcit patients that
were antipsychotic naïve and the latter did not differ from controls
(Garcia-Rizo et al., 2012).
NEUROMODULATION OF CYTOKINE PRODUCTION
Acetylcholine appears to function as an autacoid in T-cell medi-
ated immunity. ACh enhances mitogen-activated IL-2 production
and is mediated by MAPK/ERK signaling (Okuma and Nomura,
2001; Nomura et al., 2003). Conversely, ACh attenuates release
of IL-6 and is probably mediated by the muscarinic M4 receptor
(Borovikova et al., 2000; Zhang et al., 2013). Cholinergic mus-
carinic effects are reciprocal to those of β-adrenergic stimulation,
which enhances IL-6 and inhibits IL-2 production by activating
an adenylyl cyclase cAMP cascade (Kammer, 1988; Papanicolaou
et al., 1998). Akt 1 levels were signiﬁcantly reduced in schizophre-
nia (Emamian et al., 2004; van Beveren et al., 2012). Akt 1
converges with neurotrophin-associated pathways in immune reg-
ulation including IL-2 signaling. The inverse relationship between
catecholamines and muscarinic receptor function is analogous to
ﬁndings in the brain and the striatum in particular.
CYTOKINES AND A NOSOLOGY OF PSYCHOSIS
As is common with other endophenotypes not all studies are in
agreement with the above ﬁndings. There is not only interstudy,
but also intrastudy variability as would be expected from the study
of heterogeneous populations. No difference was found in IL-2
levels between schizophrenic subjects and controls in one study
of 16 paranoid types, 10 of which had a ﬁrst onset presenta-
tion (Gattaz et al., 1992). The plasma level of IL-2was signiﬁcantly
higher in a study where it correlated positively with the SAPS (Kim
FIGURE 7 | Plasma IL-2 levels in male schizophrenic patients and
normal controls (Kim et al., 2000). Notice two subgroups.
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FIGURE 8 | Iinterleukin-2 levels normalize after 8 weeks of treatment in
schizophrenic patients (Kim et al., 2000).
et al., 2000). Although, IL-6 level did not differ from controls, it
did correlate positively with the SANS and the duration of illness.
The cohort consisted of 14 paranoid and 11 undifferentiated sub-
groups. It remains plausible that the former group drove the mean
elevation in IL-2 levels and the latter IL-6. This is based on the
ﬁnding that only six patients were outside the control range for
IL-2 (Figure 7) and the measures moderated to the normal range
after 8 weeks of treatment (Figure 8). The same research group
showed higher serum levels of IL-2, but lower mitogen-induced
production of IL-2 in schizophrenic subjects compared to controls
(Kim et al., 1998). A similar argument could be invoked to explain
the differential ﬁndings in this group of nine paranoid type and
seven undifferentiated patients. The associations were not looked
at in the study presumably because of low statistical power, but
would be of some interest.
The data suggests that the majority of cases of paranoid
schizophrenia might better be grouped under a spectrum of affec-
tive psychoses where IL-2 is a state-dependent marker. Thus by
analogy, in one study of bipolar subjects levels of IL-2 and IL-
6 were increased in the manic state compared to controls, but
only IL-6 remained elevated in the depressive phase (Brietzke
et al., 2009). Mood symptoms were positively correlated with the
cytokines. A meta-analysis showed increased IL-6 in mania, nor-
malizing in the euthymic state and a trend for increases in IL-2
only in studies that used stimulation (Modabbernia et al., 2013).
Premedicated manic patients had non-signiﬁcantly higher serum
IL-2, which became signiﬁcant upon remission (Liu et al., 2004).
It is not clear why IL-2 levels were low in another anomalous study
of both manic and depressive bipolar subjects (Ortiz-Dominguez
et al., 2007).
CONCLUSION
Many factors can inﬂuence the balance between monoaminergic
and muscarinic cholinergic cascades such that variance is exhib-
ited in the full phenotypeof psychosis. However, geneticmutations
such as copy number variants (CNVs) and single nucleotide poly-
morphisms (SNPs) that result in a muscarinic signaling impair-
ment would be uniquely predictive of schizophrenic syndrome.
The grading of this signal deﬁcit would correlate with non-deﬁcit
and deﬁcit subtyping (Figure 9). In this ﬁgure schizoaffective
disorder shares the same genetic risk proﬁle as bipolar disorder
and schizophrenia. TheMaudsley twin study of non-hierarchically
FIGURE 9 |Venn diagram for a nosology of psychosis. M represents the relative muscarinic deﬁcit and correlates with primary negative symptoms. D,
dopamine receptor subtypes. D3 sensitizes M receptor function. Across the spectrum dopamine-muscarinic imbalance results in an overlapping phenotype in
positive symptoms.
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deﬁned syndromes justiﬁes this broader grouping (Cardno et al.,
2002). Symbol M refers to muscarinic transduction. CACNA1C is
a risk gene common to bipolar, schizophrenic and major depres-
sive disorders (Green et al., 2010). It codes for a subunit of the
L-type voltage-gated calcium channel.
The nomenclature is consistent with single or double allelic
deletions, but can also be viewed as relative signaling deﬁcit
where other large effect CNVs that directly impact on ele-
ments within the muscarinic pathway are yet to be discovered.
For example, M4 receptor transactivation of tyrosine kinases
(Src) and thus Akt/ERK pathways is mediated by Gβγ subunits.
Complicating matters, convergent muscarinic M1-type mediated
ERK phosphorylation involves Src-dependent, PKC-independent
transactivation of growth factor receptors or a PKC-dependent,
Src-independent pathway, as demonstrated in salivary glands (Lin
et al., 2008). This appears to be partly subtype determined, i.e.,
M1 or M3. The phenotypic expression of PLCB1 gene deletions
depend on other factors and may not be necessary or sufﬁcient to
lead to the clinical psychotic episode. Epigenetic transformation
of PLCB1 will interact with other susceptibility loci.
What then does a single case of PLCB1 deletion in the bipolar
post-mortem cohort signify with respect to the proposed model
of classiﬁcation (Lo Vasco et al., 2013). Without detailed knowl-
edge of the clinical history of the patient, which is not described in
the paper, conclusions remain speculative. However, accepting the
predictive value of a biological marker, a change in clinical diagno-
sismay bewarranted: syndromeswith single allele deletions would
be classiﬁed as non-deﬁcit and double deletions deﬁcit schizophre-
nia. It requires replication inmuch larger population samples. This
has outstanding implications for DSM classiﬁcation by addressing
the main criticism of the diagnostic system for a nosology lacking
biological validity.
The role of PLCB1 and muscarinic signaling in neurode-
velopment is likely to be rather complex. Although mutations
in the PLCB1 gene could potentially be used as a marker dif-
ferentiating a nosology of psychosis, the converse does not
necessarily apply. This caveat refers to variance in pheno-
typic expression outside the psychotic domain. Thus, single
case reports of deletions in chromosome 20p12.3 that disrupts
PLCB1 and compound heterozygous gene mutations were impli-
cated in intractable early infantile epilepsy (Kurian et al., 2010;
Ngoh et al., 2014). In the latter study heterozygous deletion was
detected in the mother and a separate mutation in the father.
Both parents were apparently healthy, demonstrating incomplete
penetrance of either disorder. There is a well-known overlap
in genetic liability for epilepsy and schizophrenia. Obviously,
M−/− does not imply complete abrogation of function as some
functional reserve or compensatory epigenetic changes will be
consistent with non-lethality or absence of severe intellectual
disability.
In these rare cases of infantile epilepsy the promotor sequence
and ﬁrst three coding exons are deleted. The probe for PLCB1
in the Lo Vasco study was 115.611 bp long spanning from exon
19 to 32. PLCB1 transcripts are alternatively spliced, but promo-
tor deletion resulted in silencing of all the transcripts (Kurian
et al., 2010). The limited data on schizophrenia suggests that dele-
tions should allow functional transcripts of the mutated gene, but
of signiﬁcantly reduced potency. Of course, other factors might
contribute to haplosufﬁciency, haploinsufﬁciency and incomplete
dominance of the mutated allele. With adequate reﬁnement of
the probing technique and more data on PLCB1 mutations in
schizophrenia, even a more accurate premorbid prediction might
be possible.
Ultimately, coherent expression of emotions would depend on
the integrity of PI3K/Akt or Raf/ERK pathways, but transduction
oversensitivity of the same convergent pathways in theory, results
in affective dysregulation. Clinical separation of an affective spec-
trum disorder from a diagnosis of schizophrenia with depressive
features can often be tricky, so the value of a deﬁnitive genetic
marker is obvious. There is also the potential of such a major
genetic ﬁnding to help arbitrate when psychotic members of the
same family are given different diagnoses.
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